We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

CAR-T Cell Immunotherapy for HCC Targeting GPC3

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02723942
Recruitment Status : Withdrawn (Project terminated due to revision of local regulations)
First Posted : March 31, 2016
Last Update Posted : July 16, 2020
Information provided by (Responsible Party):
Fuda Cancer Hospital, Guangzhou

Brief Summary:
The purpose of this study is to preliminarily evaluate the safety and efficacy of CAR-T cell immunotherapy for GPC3 positive hepatocellular carcinoma.

Condition or disease Intervention/treatment Phase
GPC3 Positive Hepatocellular Carcinoma CAR-T Cell Immunotherapy Biological: CAR-T cell immunotherapy Phase 1 Phase 2

Detailed Description:
Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen receptor targeting glypican-3(GPC3) antigen.After CAR-T cell infusion,At periodic intervals, the investigators will evaluate clinical symptoms Improved conditions of this disease.Through this study,the investigators will evaluate the safety and efficacy of CAR-T cell immunotherapy in treating with GPC3 positive malignant glioma patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Chimeric Antigen Receptor-Modified T Cell (CAR-T) Immunotherapy for Hepatocellular Carcinoma (HCC) Targeting Glypican-3 (GPC3)
Actual Study Start Date : June 2015
Actual Primary Completion Date : August 15, 2016
Actual Study Completion Date : August 15, 2016

Arm Intervention/treatment
Experimental: CAR-T cell immunotherapy
Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen by infusion.
Biological: CAR-T cell immunotherapy
This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.

No Intervention: no intervention
no intervention

Primary Outcome Measures :
  1. Radiological assessment [ Time Frame: 3 months ]
    Radiological assessment of the therapeutic effect by systemic or local computed Tomography(CT) or positron emission tomography scan.

Secondary Outcome Measures :
  1. The safety of CAR-T cell immunotherapy (adverse events) [ Time Frame: 4 weeks ]
    After CAR-T cell infusion,we will observe the potential adverse events related to the T-cell infusion such as high fever,jaundice, kidney failure and so on.

  2. Peripheral blood tumor markers [ Time Frame: 3 months ]
    tested regularly to reflect the role of the Chimeric Antigen Receptor-Modified T Cell in the removal of residual tumor cells.

  3. CAR-T cell testing [ Time Frame: 3 months ]
    The level of CAR-T cells will be tested regularly by Real-time Quantitative Polymerase Chain Reaction Detecting System(qPCR) or Flow cytometry to evaluate the proliferation in vivo and long-term survival.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age:18-70 years.
  2. Gender:both.
  3. GPC3 high expression hepatocellular carcinoma patients.
  4. Non diffuse hepatocellular carcinoma,no extrahepatic metastasis or portal vein vascular invasion.
  5. Degree of liver cirrhosis:class A or class B 7 according to Child-puge grading standard.
  6. Routine blood test:white blood cell count(WBC)>=3×10^9/L, Lymphocyte percentage>=15%, hemoglobinHbo(Hb)>=90g/L, prothrombin time(PT) prolongation<=50% normal value, Cluster of differentiation 3(CD3) positive T cell count>=0.8×10^9/L.
  7. Liver and Pancreatic function:Alanine aminotransferase/Aspartate transaminase(ALT/AST)<=5 times of the normal value, total bilirubin(TBiL)<=3.0mg/dL, albumin(ALB)>=35g/L, prothrombin time(PT):International Normalized Ratio(INR)<=1.7 or prothrombin time(PT) prolongation<=4s, Serum lipase<=1.5 times of the normal value, Serum amylase<=1.5 times of the normal value.
  8. Renal function:Serum creatinine(SCr)<=221μmol/L(2.5mg/L).
  9. Karnofsky Performance Status(KPS)>=60;Expected survival time>=12 weeks.
  10. Peripheral venous access ;no contraindication of lymphocyte separation.
  11. No other serious complications.
  12. Voluntarily signed informed consent.

Exclusion Criteria:

  1. Pregnant and lactating women.
  2. Lymphocyte separation or peripheral venous access cannot be performed in patients .
  3. Patients in the active stage of infection or with coagulation disorders.
  4. Patients with a previous history of hepatic coma.
  5. Patients with severe gastrointestinal ulcers or gastrointestinal bleeding.
  6. Patients with organ transplantation or waiting for organ transplantation.
  7. Patients with anticoagulant therapy.
  8. Patients with antiplatelet therapy.
  9. Serum sodium(Na)<125 mmol/L.
  10. Serum potassium(K)<3.5 mmol/L(except patients up to the standards after the use of supplements).
  11. Patients with organ failure:

    1. cardiac function:level three or above according to New York Heart Association (NYHA) criteria.
    2. liver function:class C or above according to Child-puge grading standard.
    3. renal function:Chronic kidney disease(CKD) phase 4 or more; renal insufficiency phase Ⅲ or more.
    4. pulmonary function:severe respiratory failure symptoms, involving other organs.
    5. Brain function:central nervous system abnormalities or disturbance of consciousness.
  12. Patients with non controlled infectious diseases,for example,HIV positive, syphilis, hepatitis A, hepatitis B, hepatitis C, hepatitis E virus (HEV) positive etc.
  13. Patients used corticosteroids or other immunosuppressive agents in the past 4 weeks.
  14. Patients with autoimmune disease.
  15. Patients with previous history of gene therapy.
  16. The actual transfection rate of T cells was lower than 30% or the proliferation was less than 5 times after costimulation.
  17. Patients participated in other drug trials in the past 4 weeks.
  18. Patients received radiation treatment in the past 4 weeks.
  19. Patients do not meet the criteria above.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02723942

Layout table for location information
China, Guangdong
Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong, China, 510000
Sponsors and Collaborators
Fuda Cancer Hospital, Guangzhou
Layout table for investigator information
Study Chair: Lizhi Niu, PhD Fuda Cancer Hospital
Layout table for additonal information
Responsible Party: Fuda Cancer Hospital, Guangzhou
ClinicalTrials.gov Identifier: NCT02723942    
Other Study ID Numbers: CAR-T for GPC3+ HCC
First Posted: March 31, 2016    Key Record Dates
Last Update Posted: July 16, 2020
Last Verified: July 2020
Keywords provided by Fuda Cancer Hospital, Guangzhou:
chimeric antigen receptor-modified T cell(CAR-T)
hepatocellular carcinoma(HCC)
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Immunomodulating Agents
Immunologic Factors
Physiological Effects of Drugs